Shots:

• The companies will initiate P-I/II study evaluating the safety and preliminary efficacy of BBP-398 in combination with both Opdivo as dual therapy & Opdivo + KRASG12C inhibitor as triplet therapy in NSCLC patients with KRAS mutations- as 1L & 2L treatment options
• BridgeBio will sponsor the study while BMS will provide nivolumab to the study. Both the companies will share the cost of clinical development activities for the combination study
• BridgeBio is currently advancing its P-I trial in patients with solid tumors driven by mutations in the MAPK signaling pathway- including RAS and receptor tyrosine kinase genes

 Ref: BridgeBio | Image: BMS